Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Addition Therapeutics develops RNA-only therapeutics using PRINT technology for genetic medicine.
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment.
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.
Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ.
Tizona develops next-generation immunotherapies
DescriptionIFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.
Virion Biotherapeutics is a developer of biological antivirals creates to offer improved therapeutics for respiratory viral infections.
Wilson Therapeutics focuses on developing novel therapies addressing unmet medical needs in rare diseases.
Abingworth has invested in 50 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Abingworth's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Pharmaceutical. The firm invests across 17 different industry categories.
Among tracked funding rounds, Tizona Therapeutics received $300.0M in a Corporate Round round. Abingworth's total known invested capital is $5.2B.
Abingworth's average investment size is $126.9M across its portfolio of 50 companies.
Recent Abingworth portfolio additions include Addition Therapeutics, Solve Therapeutics, R1 Therapeutics, Spruce Biosciences, Vera Therapeutics. These companies were founded in 2020 or later.